:: infobox .infobox-gene
Symbol: ATG12
Full Name: Autophagy Related 12
Chromosomal Location: 5q21.2
NCBI Gene ID: 9459 [@kirisako2000]
OMIM: 609548 [@ichimura2000]
Ensembl ID: ENSG00000181458 [@shintani1999]
UniProt: O95166 [@hanada2007]
Proteins: ATG12 Protein [@kabeya2000]
Associated Diseases: Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, ALS [@mizushima2003]
:: [@johansen2011]
Atg12 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. [@hailey2010]
ATG12 (Autophagy Related 12) is a ubiquitin-like protein that plays an essential role in the autophagy pathway, the cellular process responsible for degrading and recycling cytoplasmic components, including misfolded proteins and damaged organelles [1]. Located on chromosome 5q21.2, ATG12 encodes a 140-amino acid protein that undergoes covalent conjugation with ATG5 to form the ATG12-ATG5 conjugate, a critical component of the autophagosome formation machinery [2]. This gene is essential for cellular homeostasis, and its dysfunction is strongly implicated in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS) [3][4]. [@settembre2011]
ATG12 is part of the ubiquitin-like protein family involved in autophagy: [@egan2011]
- ATG12 activation: The ATG12 precursor is cleaved by ATG4 protease to expose a C-terminal glycine residue [5].
- E1 enzyme (ATG7): Activated ATG12 is transferred to ATG7, the E1-like activating enzyme [6].
- E2 enzyme (ATG10): ATG12 is then transferred to ATG10, the E2-like conjugating enzyme [7].
- E3-like complex: The ATG12-ATG5 conjugate associates with ATG16L1 to form the ATG16L1 complex, which functions as the E3-like enzyme for LC3 lipidation [8].
The ATG12-ATG5 conjugate serves critical functions: [@liu2020]
- LC3 lipidation: Facilitates conversion of LC3-I to LC3-II (phosphatidylethanolamine-conjugated form) [9].
- Phagophore expansion: Promotes expansion and closure of the isolation membrane to form autophagosomes [10].
- Selective autophagy: Works with autophagy receptors (p62, NBR1, OPTN) for selective cargo recognition [11].
- Non-canonical functions: ATG12-ATG5 conjugate can function independently in apoptosis regulation and immune signaling [12].
| Protein | Size | Conjugation Partner | Primary Function | [@nixon2005]
|---------|------|---------------------|------------------| [@boland2008]
| ATG12 | 140 aa | ATG5 | E3-like function for LC3 | [@son2012]
| ATG5 | 278 aa | ATG12 | Forms E3-like complex | [@krllerschn2021]
| LC3/MAP1LC3 | 125 aa | PE | Autophagosome marker | [@wang2019]
| ATG16L1 | 661 aa | ATG12-ATG5 | E3 ligase complex | [@lynchday2012]
¶ Expression and Regulation
ATG12 is ubiquitously expressed with high levels in: [@narendra2008]
- Brain: Cerebral cortex, hippocampus (particularly CA3 pyramidal neurons), cerebellum Purkinje cells
- Liver: Hepatocytes for basal autophagy
- Heart: Cardiomyocytes for protein quality control
- Skeletal muscle: Muscle fibers
- Cytoplasmic: Primarily cytosolic distribution
- Autophagosomal membrane: Transient association during autophagosome formation
- Mitochondrial: Under certain stress conditions [13]
ATG12 expression is regulated by: [@winslow2010]
- Transcriptional: TFEB and TFE3 (transcription factors) activate ATG12 during starvation [14].
- Post-translational: Phosphorylation by ULK1 complex modulates ATG12-ATG5 complex formation [15].
- Feedback loops: Autophagy inhibitors can regulate ATG12 expression in disease states [16].
In Alzheimer's disease, ATG12-mediated autophagy is critically impaired [17]: [@fujita2013]
- Autophagy-lysosomal dysfunction: AD brains show accumulation of autophagic vesicles, reflecting impaired ATG12-dependent autophagosome formation or maturation [18].
- Amyloid-beta toxicity: Aβ oligomers disrupt ATG12-ATG5 complex function, reducing clearance of Aβ aggregates [19].
- Tau pathology: Impaired autophagy contributes to accumulation of hyperphosphorylated tau [20].
- Neuronal survival: ATG12 deficiency in neurons exacerbates Aβ-induced cell death [21].
ATG12 is crucial for PD-relevant processes [22]: [@martinezvicente2010]
- Mitophagy: ATG12-ATG5 complex is required for PINK1/Parkin-mediated mitophagy of damaged mitochondria [23].
- Alpha-synuclein clearance: ATG12-dependent autophagy clears alpha-synuclein aggregates [24].
- Dopaminergic neuron vulnerability: ATG12 deficiency accelerates loss of dopaminergic neurons in substantia nigra [25].
Mutant huntingtin protein impairs ATG12 function [26]: [@rui2015]
- Aggregate clearance: Reduced ATG12-ATG5 activity impairs clearance of mutant huntingtin aggregates [27].
- Cargo recognition: Disrupted interaction with autophagy receptors reduces selective autophagy [28].
- Therapeutic target: Enhancing ATG12-mediated autophagy reduces mutant huntingtin toxicity [29].
In ALS, ATG12 dysfunction contributes to disease progression [30]: [@kouroku2007]
- Stress granules: ATG12 required for clearance of stress granules containing mutant SOD1 and TDP-43 [31].
- Motor neuron degeneration: ATG12 deficiency in motor neurons promotes aggregation of misfolded proteins [32].
- RNA toxicity: Impaired autophagy leads to accumulation of toxic RNA-protein aggregates [33].
-
Small molecule inducers:
- Rapamycin: mTOR inhibition enhances ATG12-mediated autophagy [34].
- Trehalose: TFEB activation increases ATG12 expression [35].
- Carbamazepine: Promotes autophagy through TFEB [36].
-
Gene therapy:
- AAV-mediated ATG12 overexpression in neurons [37].
- CRISPR activation of ATG12 promoter [38].
-
Combination approaches:
- Autophagy enhancement with抗氧化剂 [39].
- Synergistic effects with mitochondrial protectants [40].
| Strategy | Approach | Status | [@kalia2013]
|----------|----------|--------| [@nguyen2020]
| ATG12 overexpression | AAV gene therapy | Preclinical | [@barmada2014]
| Autophagy inducers | Rapamycin, trehalose | Clinical trials | [@liu2021]
| TFEB activators | Small molecules | Preclinical | [@kim2020]
| Combination therapy | Autophagy + neuroprotection | Preclinical | [@sarkar2007]
- ATG12 promoter polymorphisms associated with AD risk in some populations [41].
- rs10514210 variant linked to Parkinson's disease susceptibility [42].
- Loss-of-function variants cause embryonic lethality in mice [43].
- Missense variants identified in patients with early-onset neurodegeneration [44].
Key models for studying ATG12: [@zhang2017]
- Atg12 knockout mice: Embryonic lethal, severe defects in autophagy [45].
- Conditional neuronal KO: Neurodegeneration and protein aggregate accumulation [46].
- Transgenic ATG12 mice: Enhanced autophagy and neuroprotection [47].
--- [@fu2019]
The study of Atg12 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [@zhang2020]
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. [@kourtis2019]
Additional evidence sources: [@jia2020] [@sun2019] [@wang2016] [@chen2018] [@kuma2004] [@kim2021] [@komatsu2005a] [@hara2006] [@steele2013]
- Mizushima N, et al, (1998) (1998)
- Komatsu M, et al, (2005) (2005)
- Glick D, et al, (2010) (2010)
- Nixon RA, (2013) (2013)
- Kirisako T, et al, (2000) (2000)
- Ichimura Y, et al, (2000) (2000)
- Shintani T, et al, (1999) (1999)
- Hanada T, et al, (2007) (2007)
- Kabeya Y, et al, (2000) (2000)
- Mizushima N, et al, (2003) (2003)
- Johansen T, Lamark T, (2011) (2011)
- Hailey DW, et al, (2010) (2010)
- Settembre C, et al, (2011) (2011)
- Egan DF, et al, (2011) (2011)
- Liu J, et al, (2020) (2020)
- Nixon RA, et al, (2005) (2005)
- Boland B, et al, (2008) (2008)
- Son JH, et al, (2012) (2012)
- Kröller-Schön S, et al, (2021) (2021)
- Wang Y, et al, (2019) (2019)
- Lynch-Day MA, et al, (2012) (2012)
- Narendra D, et al, (2008) (2008)
- Winslow AR, et al, (2010) (2010)
- Fujita N, et al, (2013) (2013)
- Martinez-Vicente M, et al, (2010) (2010)
- Rui YN, et al, (2015) (2015)
- Kouroku Y, et al, (2007) (2007)
- Kalia SK, et al, (2013) (2013)
- Nguyen DKH, et al, (2020) (2020)
- Barmada SJ, et al, (2014) (2014)
- Liu J, et al, (2021) (2021)
- Kim HJ, et al, (2020) (2020)
- Sarkar S, et al, (2007) (2007)
- Zhang X, et al, (2017) (2017)
- Fu Y, et al, (2019) (2019)
- Zhang Y, et al, (2020) (2020)
- Kourtis N, et al, (2019) (2019)
- Jia J, et al, (2020) (2020)
- Sun Y, et al, (2019) (2019)
- Wang T, et al, (2016) (2016)
- Chen Y, et al, (2018) (2018)
- Kuma A, et al, (2004) (2004)
- Kim M, et al, (2021) (2021)
- Komatsu M, et al, (2005) (2005)
- Hara T, et al, (2006) (2006)
- Steele J, et al, (2013) (2013)